Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RESMED INCRMD · Entity 2692 | Chief Financial Officer | August 14, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RESMED INC
Report date August 14, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 9,072 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 9,072 · Balance 9,072 F1: Represents performance-based restricted stock units granted on June 1, 2026. The RSUs were earned on August 14, 2026, when the compensation and leadership development committee certified that the applicable performance metrics were met. RSUs vest 1/3 each year on the anniversary of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance-based restricted stock units granted on June 1, 2026. The RSUs were earned on August 14, 2026, when the compensation and leadership development committee certified that the applicable performance metrics were met. RSUs vest 1/3 each year on the anniversary of the grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EXACT SCIENCES CORP
Report date March 23, 2026 · Filed March 23, 2026
Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-03-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-23 · Grant · Acquired 89,911 · Balance 138,679 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding. Row 2 · 2026-03-23 · Disposition to issuer · Disposed 138,679 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectHeld in 401(k) Plan | 0 |
Reported balance
After 2026-03-23 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-03-23 · Disposition to issuer · Disposed 417 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-23 · Disposition to issuer · Disposed 4,395 · Balance 0 F4: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F6: At the Effective Time, each RSU granted before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F5: These RSUs vest in four equal annual installments beginning on February 27, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-23 · Disposition to issuer · Disposed 28,063 · Balance 0 F4: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7: At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time. F8: These RSUs vest in four equal annual installments beginning on February 25, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.
F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding.
F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
F4: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
F5: These RSUs vest in four equal annual installments beginning on February 27, 2026.
F6: At the Effective Time, each RSU granted before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding.
F7: At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.
F8: These RSUs vest in four equal annual installments beginning on February 25, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Oct 2, 2026 00:08 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 9,072 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-26-000073 · form4.xml · nonDerivative · entry 1 Bloomer Aaron · CIK 0002019003 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,072 F1 · kind: Represents performance-based restricted stock units granted on June 1, 2026. The RSUs were earned on August 14, 2026, when the compensation and leadership development committee certified that the applicable performance metrics were met. RSUs vest 1/3 each year on the anniversary of the grant. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerRestricted Stock Units · Derivative | 28,063 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118759 · ownership.xml · derivative · entry 5 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,063 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7 · price: At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time. F8 · derivative.exercise_date: These RSUs vest in four equal annual installments beginning on February 25, 2027. F8 · derivative.expiration_date: These RSUs vest in four equal annual installments beginning on February 25, 2027. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerRestricted Stock Units · Derivative | 4,395 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118759 · ownership.xml · derivative · entry 4 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,395 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F6 · price: At the Effective Time, each RSU granted before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F5 · derivative.exercise_date: These RSUs vest in four equal annual installments beginning on February 27, 2026. F5 · derivative.expiration_date: These RSUs vest in four equal annual installments beginning on February 27, 2026. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118759 · ownership.xml · nonDerivative · entry 3 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Held in 401(k) Plan Disclosed balance after: 0 F3 · price: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 138,679 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118759 · ownership.xml · nonDerivative · entry 2 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 89,911 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-118759 · ownership.xml · nonDerivative · entry 1 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,679 F1 · shares: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. F2 · shares: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantRestricted Stock Units · Derivative | 28,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-082834 · ownership.xml · derivative · entry 3 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,063 Underlying: Common Stock · 28,063 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on February 25, 2027. F3 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on February 25, 2027. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 24,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337151 · ownership.xml · derivative · entry 7 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,395 Underlying: Common Stock · 24,384 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: This award was scheduled to vest in four equal installments on February 27, 2026, February 26, 2027, February 29, 2028, and February 28, 2029, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. F6 · derivative.expiration_date: This award was scheduled to vest in four equal installments on February 27, 2026, February 26, 2027, February 29, 2028, and February 28, 2029, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 38,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337151 · ownership.xml · derivative · entry 6 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: This award was scheduled to vest in three equal installments on April 15, 2026, April 15, 2027, and April 15, 2028, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. F5 · derivative.expiration_date: This award was scheduled to vest in three equal installments on April 15, 2026, April 15, 2027, and April 15, 2028, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 10,803 | $101.82 | $1,099,961.46 |
DisclosureSEC source: 0001193125-25-337151 · ownership.xml · nonDerivative · entry 4 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,768 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation (the "Issuer") for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 48,980 shares, Mr. Bloomer also holds, in the aggregate, an additional 4,395 unvested restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 24,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337151 · ownership.xml · nonDerivative · entry 3 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 17,151 | $101.82 | $1,746,314.82 |
DisclosureSEC source: 0001193125-25-337151 · ownership.xml · nonDerivative · entry 2 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,187 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation (the "Issuer") for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 38,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337151 · ownership.xml · nonDerivative · entry 1 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 12,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-055422 · ownership.xml · derivative · entry 7 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,715 Underlying: Common Stock · 12,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Represents a restricted stock unit award granted on April 15, 2024 that vests in four equal annual installments from the grant date. F6 · derivative.expiration_date: Represents a restricted stock unit award granted on April 15, 2024 that vests in four equal annual installments from the grant date. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 11,566 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-055422 · ownership.xml · derivative · entry 6 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,566 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on April 15, 2024 that vested in full on the one-year anniversary of the grant date. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on April 15, 2024 that vested in full on the one-year anniversary of the grant date. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 5,717 | $44.25 | $252,977.25 |
DisclosureSEC source: 0000950170-25-055422 · ownership.xml · nonDerivative · entry 4 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,623 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 13,835 shares, Mr. Bloomer also holds, in the aggregate, an additional 67,494 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 12,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-055422 · ownership.xml · nonDerivative · entry 3 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 5,120 | $44.25 | $226,560.00 |
DisclosureSEC source: 0000950170-25-055422 · ownership.xml · nonDerivative · entry 2 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,436 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 11,556 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-055422 · ownership.xml · nonDerivative · entry 1 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 20:00 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantRestricted Stock Units · Derivative | 28,779 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-028167 · ownership.xml · derivative · entry 1 Bloomer Aaron · CIK 0002019003 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,779 Underlying: Common Stock · 28,779 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on February 27, 2026. F2 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on February 27, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.